Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel-trastuzumab in EGFR-mutated NSCLC
NCT02226757Phase 2Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2014
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02226757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226757.